Genstar Capital Promotes Two to Principal
Genstar Capital, LLC, a middle-market private equity firm that focuses on investments in selected segments of the insurance and financial services, software, life sciences, healthcare and industrial technology industries, announced the promotions of Rob S. Rutledge and Anthony J. Salewski to principal. Both were previously Genstar vice presidents.
“Rob and Tony have made exceptional contributions to our firm and their advancement to senior leadership positions is a recognition of their roles as valuable members of our team. They combine a strong investment experience with an ability to work very well within our firm’s entrepreneurial management culture to drive change at our portfolio investments and create value for our investors,” said Jean-Pierre L. Conte, managing director and chairman of Genstar.
Rutledge was named a vice president of Genstar in 2010. Prior to re-joining Genstar as a senior associate in 2007, he spent two years as an associate at Genstar from 2003 to 2005 and also served as an associate in the investment banking division of Salomon Smith Barney in San Francisco. Rutledge began his career in the investment banking division of Salomon Smith Barney in New York. He earned an MBA from Stanford University and received a Bachelor of Commerce from Queen’s University. Today, he serves on the Boards of Genstar portfolio companies Confie Seguros, Granite Global Solutions, MW Industries, Inc., Univita Health and Voice Construction.
Salewski joined Genstar in 2007 and has served as a vice president since 2010. Prior to joining Genstar, he was the chief of Staff for Operations at Barclays Global Investors (BGI). Prior to BGI, Salewski was an associate at Hellman & Friedman LLC. He began his career in the investment banking division of Morgan Stanley in New York. Salewski received an MBA with distinction from Harvard Business School and graduated with honors from Harvard College. Today, he serves on the Boards of Genstar portfolio companies Travelclick and MidCap Financial, and is a board observer at Catalent Pharma Solutions.